Neuroprotective effect of dexmedetomidine in a murine model of traumatic brain injury

Jin Wu, Todd Vogel, Xiang Gao, Bin Lin, Charles Kulwin, Jinhui Chen

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

No FDA approved pharmacological therapy is available that would reduce cell death following traumatic brain injury (TBI). Dexmedetomidine (Dex) is a highly selective agonist of alpha-2 adrenergic receptors and has demonstrated neuroprotective effects in hippocampal slice cultures undergoing direct impact. However, no one has tested whether Dex, in addition to its sedative action, has neuroprotective effects in an animal model of TBI. Thus, in the present study, we investigated the effects of Dex on an animal model of TBI. Mice received different doses of Dex (1, 10, or 100 μg/kg bodyweight, n = 10 each group) or saline as control at 1 hour and 12 hours following TBI. The mice treated with Dex lost less cortical tissue than the control mice. Further analysis found that Dex treatment reduced cell death in the cortex and the hippocampus measured by Fluoro-Jade B (FJB) staining, prevented axonal degeneration detected by immunostaining with antibody against β-amyloid precursor protein (β-APP), and protected synapses from elimination with synaptophysin staining. Taken together, in an in vivo murine model of TBI, Dex at the dose of 100 μg/kg not only prevented tissue lesion and cell death, but also reduced axonal injury and synaptic degeneration caused by TBI.

Original languageEnglish (US)
Article number4935
JournalScientific Reports
Volume8
Issue number1
DOIs
StatePublished - Dec 1 2018

Fingerprint

Dexmedetomidine
Neuroprotective Agents
Cell Death
Animal Models
Adrenergic alpha-2 Receptor Agonists
Staining and Labeling
Synaptophysin
Amyloid beta-Protein Precursor
Traumatic Brain Injury
Hypnotics and Sedatives
Synapses
Hippocampus
Pharmacology
Antibodies
Wounds and Injuries

ASJC Scopus subject areas

  • General

Cite this

Neuroprotective effect of dexmedetomidine in a murine model of traumatic brain injury. / Wu, Jin; Vogel, Todd; Gao, Xiang; Lin, Bin; Kulwin, Charles; Chen, Jinhui.

In: Scientific Reports, Vol. 8, No. 1, 4935, 01.12.2018.

Research output: Contribution to journalArticle

Wu, Jin ; Vogel, Todd ; Gao, Xiang ; Lin, Bin ; Kulwin, Charles ; Chen, Jinhui. / Neuroprotective effect of dexmedetomidine in a murine model of traumatic brain injury. In: Scientific Reports. 2018 ; Vol. 8, No. 1.
@article{e5ac5c8946fe4806a8218fe174848d17,
title = "Neuroprotective effect of dexmedetomidine in a murine model of traumatic brain injury",
abstract = "No FDA approved pharmacological therapy is available that would reduce cell death following traumatic brain injury (TBI). Dexmedetomidine (Dex) is a highly selective agonist of alpha-2 adrenergic receptors and has demonstrated neuroprotective effects in hippocampal slice cultures undergoing direct impact. However, no one has tested whether Dex, in addition to its sedative action, has neuroprotective effects in an animal model of TBI. Thus, in the present study, we investigated the effects of Dex on an animal model of TBI. Mice received different doses of Dex (1, 10, or 100 μg/kg bodyweight, n = 10 each group) or saline as control at 1 hour and 12 hours following TBI. The mice treated with Dex lost less cortical tissue than the control mice. Further analysis found that Dex treatment reduced cell death in the cortex and the hippocampus measured by Fluoro-Jade B (FJB) staining, prevented axonal degeneration detected by immunostaining with antibody against β-amyloid precursor protein (β-APP), and protected synapses from elimination with synaptophysin staining. Taken together, in an in vivo murine model of TBI, Dex at the dose of 100 μg/kg not only prevented tissue lesion and cell death, but also reduced axonal injury and synaptic degeneration caused by TBI.",
author = "Jin Wu and Todd Vogel and Xiang Gao and Bin Lin and Charles Kulwin and Jinhui Chen",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41598-018-23003-3",
language = "English (US)",
volume = "8",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Neuroprotective effect of dexmedetomidine in a murine model of traumatic brain injury

AU - Wu, Jin

AU - Vogel, Todd

AU - Gao, Xiang

AU - Lin, Bin

AU - Kulwin, Charles

AU - Chen, Jinhui

PY - 2018/12/1

Y1 - 2018/12/1

N2 - No FDA approved pharmacological therapy is available that would reduce cell death following traumatic brain injury (TBI). Dexmedetomidine (Dex) is a highly selective agonist of alpha-2 adrenergic receptors and has demonstrated neuroprotective effects in hippocampal slice cultures undergoing direct impact. However, no one has tested whether Dex, in addition to its sedative action, has neuroprotective effects in an animal model of TBI. Thus, in the present study, we investigated the effects of Dex on an animal model of TBI. Mice received different doses of Dex (1, 10, or 100 μg/kg bodyweight, n = 10 each group) or saline as control at 1 hour and 12 hours following TBI. The mice treated with Dex lost less cortical tissue than the control mice. Further analysis found that Dex treatment reduced cell death in the cortex and the hippocampus measured by Fluoro-Jade B (FJB) staining, prevented axonal degeneration detected by immunostaining with antibody against β-amyloid precursor protein (β-APP), and protected synapses from elimination with synaptophysin staining. Taken together, in an in vivo murine model of TBI, Dex at the dose of 100 μg/kg not only prevented tissue lesion and cell death, but also reduced axonal injury and synaptic degeneration caused by TBI.

AB - No FDA approved pharmacological therapy is available that would reduce cell death following traumatic brain injury (TBI). Dexmedetomidine (Dex) is a highly selective agonist of alpha-2 adrenergic receptors and has demonstrated neuroprotective effects in hippocampal slice cultures undergoing direct impact. However, no one has tested whether Dex, in addition to its sedative action, has neuroprotective effects in an animal model of TBI. Thus, in the present study, we investigated the effects of Dex on an animal model of TBI. Mice received different doses of Dex (1, 10, or 100 μg/kg bodyweight, n = 10 each group) or saline as control at 1 hour and 12 hours following TBI. The mice treated with Dex lost less cortical tissue than the control mice. Further analysis found that Dex treatment reduced cell death in the cortex and the hippocampus measured by Fluoro-Jade B (FJB) staining, prevented axonal degeneration detected by immunostaining with antibody against β-amyloid precursor protein (β-APP), and protected synapses from elimination with synaptophysin staining. Taken together, in an in vivo murine model of TBI, Dex at the dose of 100 μg/kg not only prevented tissue lesion and cell death, but also reduced axonal injury and synaptic degeneration caused by TBI.

UR - http://www.scopus.com/inward/record.url?scp=85044413979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044413979&partnerID=8YFLogxK

U2 - 10.1038/s41598-018-23003-3

DO - 10.1038/s41598-018-23003-3

M3 - Article

VL - 8

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 4935

ER -